BE-101 is a single IV infusion which does not require preconditioning or immunosuppression in recipients.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Visit our sister site Blood Cancers Today for more blood cancers and hematology news
Latest News
Nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, showed clinical activity in a phase 1/2 study.
Concizumab-mtci improves thrombin production by blocking the tissue factor pathway inhibitor protein.
In the phase 3 explorer8 trial, concizumab reduced the bleeding rate in patients with hemophilia A and B.
The phase 2a trial is investigating the safety and efficacy of HBI-002, an oral low-dose carbon monoxide therapy.
The agent is already approved to treat thrombocytopenia in adults with chronic ITP for whom prior therapy was unsuccessful.
Annette Von Drygalski, MD, PharmD, discussed the promising role of etranacogene dezaparvovec gene therapy in hemophilia B.
Safi Biotherapeutics expects to initiate a clinical trial in 2027 following completion of IND-enabling activities.
The primary end point for RBC transfusion independence was not met but the cohort still had significant anemia improvement.
Oral avatrombopag shows promise in kids with ITP, offering a safer, effective alternative to current treatments.
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
Conference Coverage
Major highlights with a focus on MDS from the 66th American Society of Hematology Annual Meeting & Exposition
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
Knowledge Hubs
Visit our sister site Blood Cancers Today for more blood cancers and hematology news
Latest From Blood Cancers Today
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.